NEWS
Paul Hastings Advises the Underwriters on Kailera Therapeutics’ $625 Million IPO
April 17, 2026
Paul Hastings LLP advised J.P. Morgan Securities, Jefferies, Leerink, TD Cowen and Evercore as joint book-running managers in Kailera Therapeutics’ (Nasdaq: KLRA) $625 million IPO of 39,062,500 shares of its common stock at a price of $16.00 per share. Kailera has also granted the underwriters a 30-day option to purchase 5,859,375 additional shares at the initial public offering price, less underwriting discounts and commissions. The transaction is expected to close on April 20, 2026, subject to customary closing conditions.
The offering is the largest biotech IPO ever completed.
Kailera is an advanced clinical-stage biotechnology company developing a range of treatments to improve obesity care and provide options for patients at every stage of their journey.
Equity Capital Markets and Corporate Life Sciences chair Seo Salimi led the Paul Hastings team, which included of counsel Ryan Brewer and associates Chris Guerin and Adam Swank.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.